Dr. Debra S. Brandt
Claim this profileJupiter Medical Center
Studies Breast Cancer
Studies Cancer
8 reported clinical trials
19 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
ER positive
PR positive
2Cancer
ER positive
PR positive
HER2 negative
Affiliated Hospitals
Clinical Trials Debra S. Brandt is currently running
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
More about Debra S. Brandt
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Debra S. Brandt has experience with
- Paclitaxel
- Cyclophosphamide
- Carboplatin
- Durvalumab
- Stereotactic Body Radiation Therapy
- Doxorubicin Hydrochloride
Breakdown of trials Debra S. Brandt has run
Breast Cancer
Cancer
Endometrial Carcinoma
Serous Cystadenocarcinoma
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Debra S. Brandt specialize in?
Debra S. Brandt focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are ER positive.
Is Debra S. Brandt currently recruiting for clinical trials?
Yes, Debra S. Brandt is currently recruiting for 5 clinical trials in Jupiter Florida. If you're interested in participating, you should apply.
Are there any treatments that Debra S. Brandt has studied deeply?
Yes, Debra S. Brandt has studied treatments such as Paclitaxel, Cyclophosphamide, Carboplatin.
What is the best way to schedule an appointment with Debra S. Brandt?
Apply for one of the trials that Debra S. Brandt is conducting.
What is the office address of Debra S. Brandt?
The office of Debra S. Brandt is located at: Jupiter Medical Center, Jupiter, Florida 33458 United States. This is the address for their practice at the Jupiter Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.